Neurodegenerative disease management最新文献_第2页

Gait assessment using wearable technologies in neurological disorders: a rapid umbrella. 在神经系统疾病中使用可穿戴技术进行步态评估：一把快速保护伞。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-30 DOI: 10.1080/17582024.2025.2560775

Prajakta P Masurkar, Sagar Rikame

{"title":"Gait assessment using wearable technologies in neurological disorders: a rapid umbrella.","authors":"Prajakta P Masurkar, Sagar Rikame","doi":"10.1080/17582024.2025.2560775","DOIUrl":"https://doi.org/10.1080/17582024.2025.2560775","url":null,"abstract":"Background: Gait analysis is essential tool for tracking neurological disorders-Parkinson's disease (PD), stroke, Alzheimer's disease (AD), and multiple sclerosis (MS). Wearable technologies enable continuous, noninvasive gait tracking beyond clinical settings but face challenges in accuracy and adoption. This review investigates wearable gait assessment, identifying patterns and future needs.Methods: This rapid umbrella review was conducted, synthesizing systematic reviews and meta-analyses of wearable technologies for gait assessment in PD, stroke, AD, and MS. Following PRISMA guidelines two reviewers screened, extracted data on gait outcomes, and assessed quality using AMSTAR-2.Results: Seventeen reviews (13systematic, 4meta-analyses) encompassing 308 primary studies were included. Most focused-on PD (n = 12), followed by stroke (n = 8), MS (n = 4), and AD (n = 2). Gait was primary outcome, alongside balance, fall risk, and mobility. Wearables (e.g. inertial sensors,) showed good diagnostic accuracy. Real-time biofeedback and exoskeletons improved function. Sensor placement differed greatly, usability was underreported.Conclusions: Lack of standardization, validation, and usability limits clinical adoption. Future efforts must prioritize real-world testing and user-centered design.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

N-acetylcysteine for Parkinson's disease: a translational systematic review of mechanistic and early clinical data. n -乙酰半胱氨酸治疗帕金森病：机制和早期临床数据的翻译系统综述。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-24 DOI: 10.1080/17582024.2025.2563489

Anas Mohammad, Mohammad Ibrahim, Moeez Akram, Hadia Mohsin, Muhammad Taaib Imran, Hassam Nasir Khan Alizai

{"title":"N-acetylcysteine for Parkinson's disease: a translational systematic review of mechanistic and early clinical data.","authors":"Anas Mohammad, Mohammad Ibrahim, Moeez Akram, Hadia Mohsin, Muhammad Taaib Imran, Hassam Nasir Khan Alizai","doi":"10.1080/17582024.2025.2563489","DOIUrl":"https://doi.org/10.1080/17582024.2025.2563489","url":null,"abstract":"Background: Parkinson's disease (PD) involves progressive motor and non-motor decline, linked to oxidative stress and glutathione depletion. N-acetylcysteine (NAC), a glutathione precursor and antioxidant, is a potential disease-modifying therapy.Objective: To evaluate preclinical and clinical evidence on NAC in PD, focusing on motor and non-motor outcomes, dopaminergic function, and oxidative stress biomarkers.Methods: A PRISMA-compliant review of MEDLINE and Embase (May 2025) identified prospective studies in animal models or adults with PD. Outcomes included Unified Parkinson's Disease Rating Scale (UPDRS), dopamine transporter (DAT) imaging, glutathione levels, and safety.Results: Twelve studies met criteria. Preclinical models showed consistent neuroprotection. Intravenous NAC raised brain glutathione levels; high-dose oral NAC reached CSF. Two open-label trials (n = 65), reported ~ 13% improvement in UPDRS scores and 4-9% dopamine transporter signal increases over three months. No serious adverse events were attributed to NAC.Conclusions: Larger randomized controlled trials are needed to test efficacy and disease-modifying potential.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-12"},"PeriodicalIF":3.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review. 雷公藤甲素对阿尔茨海默病临床前模型进展的影响：系统综述。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-24 DOI: 10.1080/17582024.2025.2562776

Rabab Shami, Rania El Majzoub, Ali Ismail, Jana Kotaich, Mariam Kassem, Ghida Safadieh, Mohammad Fayyad-Kazan, Bahia Chahine

{"title":"Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review.","authors":"Rabab Shami, Rania El Majzoub, Ali Ismail, Jana Kotaich, Mariam Kassem, Ghida Safadieh, Mohammad Fayyad-Kazan, Bahia Chahine","doi":"10.1080/17582024.2025.2562776","DOIUrl":"https://doi.org/10.1080/17582024.2025.2562776","url":null,"abstract":"Aim: This study aims to systematically evaluate and synthesize preclinical evidence on the neuroprotective effects of Triptolide (Tri) in Alzheimer's disease (AD) models, focusing on its impact on amyloid-beta accumulation, synaptic dysfunction, neuroinflammation, oxidative stress, autophagy, and apoptosis.Introduction: AD is the most common cause of dementia, yet current treatments largely target symptoms rather than underlying pathology. Tri, a bioactive compound from Tripterygium wilfordii, has shown promise due to its anti-inflammatory, antioxidant, and neuroprotective properties.Methods: A systematic search of PubMed, Embase, and Web of Science was conducted up to 16 March 2024. English-language in vivo and in vitro studies on Tri's effects in AD models were included. Methodological quality was assessed using SYRCLE and SciRAP tools. The review is registered in PROSPERO (CRD42024521822).Results: Out of 403 studies, 15 met the inclusion criteria (6 in vivo, 8 in vitro, 1 both). Tri reduced Aβ burden, enhanced memory and synaptic integrity, suppressed neuroinflammation and oxidative stress, and modulated autophagy and apoptosis.Conclusion: Tri demonstrates significant multi-target neuroprotective effects in AD preclinical models. Further high-quality studies are warranted to optimize dosing, delivery, and safety for clinical translation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-13"},"PeriodicalIF":3.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145131581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in mortality in elderly patients with Alzheimer's dementia and aspiration pneumonitis in the United States. 美国老年阿尔茨海默氏痴呆和吸入性肺炎患者死亡率趋势

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-19 DOI: 10.1080/17582024.2025.2562772

Hammad Jehangir, Ahmed Faizan, Dilawar Khan, Zain Shahzad, Muhammad Asfandyar Nadir

{"title":"Trends in mortality in elderly patients with Alzheimer's dementia and aspiration pneumonitis in the United States.","authors":"Hammad Jehangir, Ahmed Faizan, Dilawar Khan, Zain Shahzad, Muhammad Asfandyar Nadir","doi":"10.1080/17582024.2025.2562772","DOIUrl":"https://doi.org/10.1080/17582024.2025.2562772","url":null,"abstract":"Background: Alzheimer's dementia (AD) affects 6.9 million senior Americans and is a leading cause of death. Aspiration pneumonia carries high mortality but remains underexamined in this group. This study explores mortality patterns in this group to identify disparities among demographics.Methods: We analyzed data from the CDC WONDER, focusing on mortality caused by the co-occurrence of AD and aspiration pneumonitis in adults aged 65 years and older from 1999 to 2020. Joinpoint Regression Program was employed to evaluate temporal trends. Age-adjusted mortality rates (AAMRs), crude mortality rates (CMRs) and annual percent changes (APCs) were computed.Results: A total of 335,458 deaths occurred due to AD and aspiration pneumonia. The overall AAMR increased, with a significant increase from 1999 to 2001. Men had consistently higher AAMRs than women. AAMRs were highest among non-Hispanic (NH) Whites and lowest in NH Asians. CMR for the 85+ year age group was nearly four times higher than the 75-84 year age group.Conclusion: Aspiration pneumonitis caused a large number of deaths in older adults with AD with some groups being more vulnerable. These results point to ongoing disparities and emphasize the importance of better preventive care and targeted interventions to reduce preventable deaths in these vulnerable groups.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145086653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reviving mitochondria to restore the mind: stem cell-based bioenergetic rescue in Parkinson's disease. 恢复线粒体以恢复心智：基于干细胞的帕金森氏症生物能量救援。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-19 DOI: 10.1080/17582024.2025.2562741

Supriya Shidhaye, Anis Ahmad Chaudhary, Mayuri Gajghate, Priyanka Singanwad, Milind Umekar, Neha Raut, Hassan Ahmad Rudayni, Rashmi Trivedi

{"title":"Reviving mitochondria to restore the mind: stem cell-based bioenergetic rescue in Parkinson's disease.","authors":"Supriya Shidhaye, Anis Ahmad Chaudhary, Mayuri Gajghate, Priyanka Singanwad, Milind Umekar, Neha Raut, Hassan Ahmad Rudayni, Rashmi Trivedi","doi":"10.1080/17582024.2025.2562741","DOIUrl":"https://doi.org/10.1080/17582024.2025.2562741","url":null,"abstract":"Parkinson's disease is a neurodegenerative disorder of aging with dopaminergic neuronal degeneration in the substantia nigra leading to motor dysfunction. Mitochondrial dysfunction is central to its pathophysiology, leading to oxidative stress, derangement of energy metabolism, and induction of neuronal apoptosis. Current therapeutic interventions are symptomatic but fail to stop disease progression. Stem cell-based regenerative strategies have been recognized as potential disease-modifying treatments. Mitochondria-augmented stem cell therapy offers a new mechanism for the correction of cellular bioenergetic deficits. Through genetic manipulations or preconditioning protocols, mesenchymal stem cells and induced pluripotent stem cells are engineered to enhance mitochondrial function and transfer. The engineered cells enable delivery of functional mitochondria into damaged neurons through tunneling nanotubes or extracellular vesicles, promoting ATP production, inhibiting reactive oxygen species, and restoring mitophagy. Preclinical models have demonstrated improved neuronal survival and motor function, and novel technologies like CRISPR gene editing and 3D bioprinting offer improved translational relevance.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synergistic effects of curcumin-donepezil therapy in a Drosophila Alzheimer's disease model. 姜黄素-多奈哌齐治疗在果蝇阿尔茨海默病模型中的协同作用。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-14 DOI: 10.1080/17582024.2025.2558428

Opeyemi B Ogunsuyi, Odunayo O Oluokun, Adedayo O Ademiluyi, Ganiyu Oboh, Rasheedat A Akeeb, Haruna I Umar, Olawande C Olagoke

{"title":"Synergistic effects of curcumin-donepezil therapy in a Drosophila Alzheimer's disease model.","authors":"Opeyemi B Ogunsuyi, Odunayo O Oluokun, Adedayo O Ademiluyi, Ganiyu Oboh, Rasheedat A Akeeb, Haruna I Umar, Olawande C Olagoke","doi":"10.1080/17582024.2025.2558428","DOIUrl":"https://doi.org/10.1080/17582024.2025.2558428","url":null,"abstract":"Background: Despite emerging therapeutic options, Alzheimer´s disease (AD) management remains suboptimal due to multimodal pathogenesis. We investigated curcumin-donepezil combination therapy, as curcumin demonstrates antioxidant, anti-inflammatory, and anti-amyloidogenic properties that may complement donepezil's cholinesterase inhibition.Research design and methods: We employed the elav-Gal4/UAS-hAPP-BACE-1 Drosophila melanogaster model alongside molecular docking simulation and ADMET prediction to evaluate curcumin-donepezil combination versus monotherapy. Fruit flies received the treatment regimen, and were tested for survival, memory performance, and biochemical markers, including BACE-1 activity and oxidative stress parameters.Results: Combination therapy significantly improved survival rates and memory performance compared to individual treatment. The combination effectively modulated multiple AD-related pathways, demonstrating reduced BACE-1 activity and decreased oxidative stress markers. Molecular docking confirmed favorable drug interactions, and ADMET profiles supported therapeutic viability.Conclusions: Curcumin-donepezil combination therapy shows promise as a multi-target approach for AD management. However, translation to clinical applications requires validation in higher-order models and human trials.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-15"},"PeriodicalIF":3.4,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145065301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rivastigmine for parkinsonian symptoms in dementia with Lewy bodies: a paradigm shift. 利瓦斯汀治疗路易体痴呆患者帕金森症状：一种范式转变

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-12 DOI: 10.1080/17582024.2025.2558442

Porimita Chutia, Shailendra Mohan Tripathi

{"title":"Rivastigmine for parkinsonian symptoms in dementia with Lewy bodies: a paradigm shift.","authors":"Porimita Chutia, Shailendra Mohan Tripathi","doi":"10.1080/17582024.2025.2558442","DOIUrl":"https://doi.org/10.1080/17582024.2025.2558442","url":null,"abstract":"Introduction: Parkinsonian symptoms are one of the core features of Dementia with Lewy bodies (DLB), which has a prevalence of more than 80%. Management of DLB poses unique challenges as the treatment of one condition leads to the worsening of another. Rivastigmine's efficacy and tolerability for cognitive and neuropsychiatric symptoms are well-studied. However, its effect on parkinsonian symptoms of DLB is inconclusive.Clinical case series: In this case series, we elucidated five clinically diagnosed subjects of DLB with varying severity of parkinsonian motor symptoms. Beyond the cardinal signs of parkinsonism (tremor, rigidity, bradykinesia); rigidity, hypomimia, and gait disturbances were common in all the subjects. All five subjects on Rivastigmine dosage of 3-4.5 mg/day showed a greater than 50% reduction in the Unified Parkinson's Disease rating scale part III without any untoward side effects. Hypomimia, stiffness, gait, and postural abnormalities were the motor signs that were substantially improved while resting tremors showed the least improvement.Discussion: The study findings focus on the need to reflect upon the non-cholinergic deficiency hypothesis in developing motor symptoms in DLB. The distinct pathophysiology of DLB and the complex interactions of cholinergic and dopaminergic neurons in the striatum can explain the improvement in parkinsonian symptoms with Rivastigmine.Conclusion: This case series highlights the positive effect of low-dose Rivastigmine on parkinsonian motor symptoms of DLB prompting the need for further multicentric trials.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-6"},"PeriodicalIF":3.4,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of the ALSSQOL-SF in the Malaysian context through cognitive interviewing. 通过认知访谈对马来西亚背景下的ALSSQOL-SF进行评估。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-11 DOI: 10.1080/17582024.2025.2558342

Wafa' Sabirin, Saiful Adni Abd Latif, Fazlina Ahmad, Sheriza Izwa Zainuddin, Chee Loong Lam, Chun Ian Soo, Sakinah Sabirin, Kee Huat Chuah, Nortina Shahrizaila, David Paul Capelle

{"title":"An evaluation of the ALSSQOL-SF in the Malaysian context through cognitive interviewing.","authors":"Wafa' Sabirin, Saiful Adni Abd Latif, Fazlina Ahmad, Sheriza Izwa Zainuddin, Chee Loong Lam, Chun Ian Soo, Sakinah Sabirin, Kee Huat Chuah, Nortina Shahrizaila, David Paul Capelle","doi":"10.1080/17582024.2025.2558342","DOIUrl":"https://doi.org/10.1080/17582024.2025.2558342","url":null,"abstract":"Background: Quality of life is an important goal of care for people living with amyotrophic lateral sclerosis (ALS) and their carers. The ALS Specific Quality of Life instrument Short Form (ALSSQOL-SF) has been translated and validated in various cultural contexts, however its utility in the Malaysian cultural context has not yet been evaluated.Methods: The quality of life of 21 patients with ALS was evaluated using the ALSSOL-SF in either the English version or translated to the Malay language. A cognitive interview approach was utilized and the responses were transcribed and thematically analyzed.Results: Culture and language-related factors affecting the application of the ALSSQOL-SF were identified. Interpretations of intimacy and religiosity varied and sometimes differed significantly from the constructs underlying the ALSSQOL-SF domains.Conclusion: The ALSSQOL-SF captured items from the physical domain better than those from the psycho-social and spiritual domains. Cognitive interviewing showed that patients mostly could not grasp the intended meaning of the items from the psycho-social and spiritual domains despite translation into the Malay language. There are limitations in adapting the ALSSQOL-SF for use in evaluation of QOL in Malaysian ALS patients. In the local setting a better understanding is needed about how aspects such as religion, intimacy and spiritual well-being are culturally reflected and expressed.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-8"},"PeriodicalIF":3.4,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Attention Gated-VGG with deep learning-based features for Alzheimer's disease classification. 基于深度学习特征的注意力门控vgg用于阿尔茨海默病分类。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-10 DOI: 10.1080/17582024.2025.2554495

Deepthi K Moorthy, P Nagaraj

引用次数: 0

Diagnostic symptoms, treatment patterns, and healthcare resource utilization in multiple system atrophy in the United States. 美国多系统萎缩的诊断症状、治疗模式和医疗资源利用。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-09-07 DOI: 10.1080/17582024.2025.2554490

Sigal Kaplan, Handing Xie, Amit Kumar

{"title":"Diagnostic symptoms, treatment patterns, and healthcare resource utilization in multiple system atrophy in the United States.","authors":"Sigal Kaplan, Handing Xie, Amit Kumar","doi":"10.1080/17582024.2025.2554490","DOIUrl":"https://doi.org/10.1080/17582024.2025.2554490","url":null,"abstract":"Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with diverse symptoms that complicate diagnosis. We aimed to characterize MSA-related symptoms, medications, and healthcare resource utilization (HCRU).Research design and methods: This retrospective cohort study used a large US claims database. Newly diagnosed patients >30 years old with ≥2 MSA diagnosis (2017 - 2021) were matched to controls. Endpoints related to MSA symptoms, prescriptions, and HCRU were compared between the two groups during the first year after diagnosis. Conditional logistic regression models examined the association between each outcome and MSA.Results: A total of 1187 MSA patients and 4748 matched-controls were compared. MSA patients had significantly higher rates of various symptoms, respectively (OR and 95% CI): orthostatic hypotension (38.7% and 0.8%; 89.6, 57.3 - 140.2); memory disorders (22.4% and 3.6%; 9.2, 7.3 - 11.6); motor symptoms (78.1% and 33.1%; 7.5, 6.4 - 8.7); falls (11.1% and 2.2%; 6.4, 4.8 - 8.5); fatigue (46.6% and 13.6%; 5.8, 5.0 - 6.7); mood disorder (62.3% and 24.2%; 5.5, 4.8 - 6.4); and urinary dysfunction (30.8% and 9.1%; 4.9, 4.1 - 5.8), among other. They also received more medications for these conditions and had higher rates of hospitalizations and other HCRU.Conclusions: This real-world study of MSA-related symptoms, treatments, and HCRU demonstrates the significant disease burden associated with MSA.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145015813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0